Research indicates that fat-free mass loss accounts for 25-40% of total weight lost during GLP-1 therapy, a rate dramatically exceeding age-related declines of approximately 8% per decade [48]
Key Takeaways GLP-1 medications can cause dizziness by altering fluid balance and increasing sodium loss through the kidneys, leading to temporary drops in blood pressure when standing
Heres a detailed plan, supported by current clinical guidance and research
38 The CardioMEMS HF System is now approved by the U.S
Shigeta T, Aoyama M, Bando YK, Monji A, Mitsui T, Takatsu M, Cheng XW, Okumura T, Hirashiki A, Nagata K, et al: Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions
Try the BMI Calculator Dual-receptor weight loss: GIP and GLP-1 activation together produce 20%+ weight loss that doesn't depend on thyroid metabolic rate Visceral fat reduction: Targets the inflammatory abdominal fat that's disproportionately improved in hypothyroid patients Inflammation suppression: 30% to 40% reduction in CRP may ease systemic autoimmune symptoms Insulin resistance correction: Restores glucose metabolism toward normal ranges, achieving weight loss that was previously blocked Cardiovascular risk reduction: Improves lipid profiles, blood pressure, and metabolic markers that are commonly improved in Hashimoto's Important Safety Information Thyroid C-Cell Warning Like all GLP-1 receptor agonists, Zepbound carries a boxed warning about thyroid C-cell tumors (medullary thyroid carcinoma, or MTC) found in animal studies
